KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Other Accumulated Expenses (2020 - 2025)

Historic Other Accumulated Expenses for Gilead Sciences (GILD) over the last 11 years, with Q3 2025 value amounting to $3.8 billion.

  • Gilead Sciences' Other Accumulated Expenses fell 2336.6% to $3.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.8 billion, marking a year-over-year decrease of 2336.6%. This contributed to the annual value of $5.5 billion for FY2024, which is 651.07% up from last year.
  • According to the latest figures from Q3 2025, Gilead Sciences' Other Accumulated Expenses is $3.8 billion, which was down 2336.6% from $3.6 billion recorded in Q2 2025.
  • In the past 5 years, Gilead Sciences' Other Accumulated Expenses registered a high of $6.1 billion during Q4 2021, and its lowest value of $3.6 billion during Q2 2025.
  • Moreover, its 5-year median value for Other Accumulated Expenses was $4.6 billion (2025), whereas its average is $4.8 billion.
  • In the last 5 years, Gilead Sciences' Other Accumulated Expenses skyrocketed by 16869.26% in 2021 and then crashed by 2546.79% in 2022.
  • Over the past 5 years, Gilead Sciences' Other Accumulated Expenses (Quarter) stood at $6.1 billion in 2021, then decreased by 25.47% to $4.6 billion in 2022, then grew by 12.01% to $5.1 billion in 2023, then grew by 6.51% to $5.5 billion in 2024, then plummeted by 31.33% to $3.8 billion in 2025.
  • Its last three reported values are $3.8 billion in Q3 2025, $3.6 billion for Q2 2025, and $4.6 billion during Q1 2025.